|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
Pharmacogenomics & Personalised Medicine | ||||||||||||||||
May 11, 2001 | ||||||||||||||||
SMi conferences, The Hatton, Hatton Gardens, London 25th to 27th September 2001 Day One – Wednesday 26th September 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Dr Francois Thomas, VP Pharmacogenomics & Medical Affairs, Genset INTRODUCTION 9.10 PHARMACOGENETICS: OPPORTUNITIES AND CHALLENGES Pharmacogenetics vs pharmacogenomics Molecular underpinnings of pharmacogenetics Adapting medicines to genetic make-up The challenge of clinical research in genetic epidemiology and pharmacogenetics Dialogue with the public and finding societal consensus: critical issues Future trends and ambitions for the industry Prof Klaus Lindpaintner, Roche Genetics, F. Hoffmann - La Roche GENOMICS SPLICE VARIANTS AS A SOURCE OF PHARMACOGENOMICS MARKERS 9.40 Identifying clinically relevant efficacy and toxicity markers Expression profiling strategies Proof-Hit: A product in cancer pharmacogenomics Expression profiles and SNPs Profile-Hit: A product to monitor adverse affects Technical platforms Laurent Bracco, Vice President, Research, ExonHit Therapeutics REVOLUTIONISING MEDICINE – THE POST-GENOMIC ERA 10.20 Clinical genomics The impact of clinical genomics on the elucidation of common diseases The importance of maintaining high quality data flow in clinical trials Challenges of high throughput screening of SNPs The benefits of using clinical trials populations for genomic studies Linking genomics with medicine: clinical resources for the post-genomic era Drug targeting: future approaches Dr Steven Butcher, Vice President, Science, Gemini Genomics 11.00 Morning Coffee GENOMICS AND THERAPEUTIC TARGET GENE DISCOVERY 11.20 Developing effective methodologies The inverse genomics approach The importance of functional genomics in linking disease related genes to functional drugs Genetic validation Requirements for drug target validation in the post-genomic era Target selection strategies in genomics Integrating genomic structure and function Dr Krishnan Nandobalan, Vice President, Product Development, Genaissance Pharmaceuticals MOLECULAR EVOLUTION 12.00 Case study: Aptagen and Protein GenesisTM What is Protein GenesisTM Integration with Enzyme EvolutionTM Advancing product development Incorporation for large-scale drug target validation Enhancing the functions of existing proteins and enyzmes Creating and testing diversity Dr Colin Higbie, President, Aptagen 12.40 Networking Lunch GENOMICS AND MEDICINE 2.00 Maximising information output in functional genomics using zinc finger proteins Overview of the applications of genomics Application of functional genomics techniques to the discovery and development of pharmaceuticals High throughput methodologies for target identification and validation Target validation using engineered zinc finger transcription factors The future of functional genomics Dr Yen Choo, Research Director, Gendaq PHARMACOGENOMICS IN ONCOLOGY 2.40 Applications Molecular profiling as a new tool for the determination of cancer classification and prognosis Pharmacogenomics in the discovery and development of anticancer drugs Defining the role of different genomic technologies Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset 3.20 Afternoon Tea DRUG DISCOVERY INTEGRATING BIOINFORMATICS TO ACCELERATE DRUG DISCOVERY 3.40 The bioinformatics revolution Integration issues in pharmaceutical informatics The interface of data analysis technologies Linking bioinformatics with proteomics and high throughput screening to improve drug development Utilising bioinformatics systems for high throughput data analysis The effective use of bioinformatics in drug design Bioinformatics & IT: enabling cutting edge drug discovery and design Dr Christos Hatzis, Co-founder & Vice President, Technology Development, Silico Insights INTEGRATING SNPS INTO THE DRUG DISCOVERY PROCESS 4.20 Developing genetic-based diagnostics using the SNP database Why are SNPs so important? The importance of characterising SNPs and haplotypes in target genes Target prioritisation: the potential of genetic polymorphisms Structural pharmacogenomics: designing new and improved drugs SNPs: improving public awareness Advancing medicine through SNP maps Dr Mark Brann, President & Chief Scientific Officer, Acadia Pharmaceuticals 5.00 Chairman’s Closing Remarks and Close of Day One Day Two – Thursday 27th September 2001 8.30 Re-registration and Coffee 9.00 Chairman's Opening Remarks Dr Leslie Hudson, Senior Vice President, Global Business Management, Head, Emerging Technologies, Pharmacia COMMERCIAL ISSUES THE BUSINESS OF GENOMICS 9.10 Personalised drugs? Applications of pharmacogenomics Pharmacogenetics – bridging the gap between gene discovery and drug development A new way for personalised medicine – to genotype or not to genotype? Targeted healthcare models Ethical, legal and social implications To know or not to know? Dr Mihael Polymeropoulos, Pharmacogenomics, Novartis IMPACT OF PHARMACOGENOMICS ON THE PHARMACEUTICAL MARKET 9.40 The industry perspective Initiating an effective pharmacogenomics strategy The direct impact on pharmaceutical R & D: target identification to validation Shaping the way pharmaceuticals are commercialised Improving decision making in R & D Market positioning Projecting the market for the future Dr Matthew Kalnik, Executive Director, Global Prescription Business, Emerging Technologies, & Head, Pharmacogenomics, Pharmacia INVESTING FOR THE FUTURE 10.20 New opportunities for pharmacogenomics Building the novel venture to create real value Delivering on the promise of pharmacogenomics Realising the opportunities Avoiding intellectual property pitfalls Creating the right business model Evaluating pharmacogenomics for the future Dr Gregory Brown, Managing Director, Head, Healthcare, Adams, Harkness & Hill 11.00 Morning coffee INTELLECTUAL PROPERTY ISSUES IN PHARMACOGENOMICS 11.20 Genetic patenting Current issues in genetic patenting Genetic polymorphisms SNPs… Making the most of your IP R&D and licensing agreements Biotech patent litigation: current infringement and validity issues Sarah Turner, Lawyer, Lovells DRUG DISCOVERY TECHNOLOGY 12.00 Realising the potential of pharmacogenomics Impact of pharmacogenomics on the drug discovery process Technology for high-throughput drug discovery from “genomics targets” The key role of informatics Potential for improving the odds for successful drug development & clinical trials Successful partnership strategies Dr Raymond Salemme, President & Chief Scientific Officer, 3D Pharmaceuticals 12.40 Networking Lunch THE SCIENCE AND BUSINESS OF PHARMACOGENOMICS 2.00 Implications for the genomics revolution Application of pharmacogenomics SNP mapping – its potentials and challenges DNA probe arrays for pharmacogenomic discovery The challenges of data management and utility Future for pharmacogenomics Dr Mark Egerton, Vice President, Incyte Pharmaceuticals FROM “ONE DRUG FITS ALL” TO PERSONALISED THERAPY 2.40 The implications of pharmacogenetics and pharmacogenomics at the individual and population level Adverse drug reactions and post marketing drug safety: is pharmacogenetics the answer? Focusing on drug response The role of pharmacogenetics, pharmacogenomics and pharmacoepidemiology in drug surveillance and effectiveness: the individual and population approaches Enhancing the value of current drugs Challenging the “one drug fits all” approach Limitations for pharmacogenetics and pharmacogenomics Dr Joan Soriano, Principal Epidemiologist, GlaxoSmithKline 3.20 Afternoon Tea FROM CORPORATE STRATEGY TO ALLIANCE STRATEGY 3.40 How can alliances contribute to success Linking alliances to corporate strategy Developing strategic vision Setting and achieving expectations for partnerships Assessing and developing winning relationships Anton Gueth, Director, Alliance Management, Eli Lilly COMMERCIAL IMPLICATIONS OF PHARMACOGENETICS 4.20 Navigating the future healthcare marketplace What are the bottlenecks in getting to market? Pharmacogenetics: altering the face of pharmaceutical marketing Improving intervention at earlier stages Implementation of new clinical regimens Novel routes for commercialisation Barriers to adopting pharmacogenetics Dr Michael Luther, Head, Strategy, Business & Product Development, Pharmacogenetics & Applied Diagnostics, GlaxoSmithKline 5.00 Chairman’s Closing Remarks and Close of Day Two Image is Everything: Public Relations & Public Perception of Biotech 25th September 2001,The Hatton, London [In association with: Aptagen] |
||||||||||||||||
Organized by: | Louise Maher | |||||||||||||||
Invited Speakers: | A unique opportunity to learn from leading industry experts including: Prof Klaus Lindpaintner, Roche Genetics, F. Hoffmann - La Roche Dr Joan Soriano, Principal Epidemiologist, GlaxoSmithKline Dr Mihael Polymeropoulos, Pharmacogenomics, Novartis Dr Michael Luther, Head, Strategy, Business & Product Development, Pharmacogenetics & Applied Diagnostics, GlaxoSmithKline Anton Gueth, Director, Alliance Management, Eli Lilly Dr Matthew Kalnik, Executive Director, Global Prescription Business, Emerging Technologies, & Head, Pharmacogenomics, Pharmacia Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset Dr Steven Butcher, Vice President, Science, Gemini Genomics Dr Krishnan Nandabalan, Vice President, Product Development, Genaissance Pharmaceuticals Dr Mark Egerton, Vice President, Incyte Pharmaceuticals Dr Mark Brann, President & Chief Scientific Officer, Acadia Pharmaceuticals Dr Raymond Salemme, President & Chief Scientific Officer, 3D Pharmaceuticals Dr Yen Choo, Research Director, Gendaq Dr Colin Higbie, President, Aptagen Dr Laurent Bracco, Vice President, Research, ExonHit Therapeutics Dr Christos Hatzis, Co-founder & Vice President, Technology Development, Silico Insights Dr Gregory Brown, Managing Director, Head, Healthcare, Adams, Harkness & Hill Sarah Turner, Lawyer, Lovells Chaired by: Dr Leslie Hudson, Senior Vice President, Global Business Management, Head, Emerging Technologies, Pharmacia Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset |
|||||||||||||||
Deadline for Abstracts: | No abstracts required | |||||||||||||||
Registration: | £1099 + VAT | |||||||||||||||
E-mail: | customer_services@smi-online.co.uk | |||||||||||||||
Posted by: | Louise Maher | |||||||||||||||
Host: | 213.38.112.46 | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |